Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Doses in Healthy Subjects

An Open-label Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI After Single and Multiple Ascending Dose Administration to Healthy Volunteers

To evaluate safety and tolerability of VM-1500A-LAI after its single and multiple intramuscular ascending dose to healthy volunteers

Study Overview

• Status: Completed
• Conditions: HIV-1-infection
• Intervention / Treatment: Drug: VM-1500A-LAI

Detailed Description

Primary Objective:

To evaluate safety and tolerability of VM-1500A-LAI after its single and multiple intramuscular ascending dose to healthy volunteers.

Secondary Objectives:

To evaluate pharmacokinetic parameters of VM-1500A after its single and multiple intramuscular ascending dose administration to healthy volunteers.

To evaluate safety and tolerability of ELPIDA®, administered in the run-in period

• Study Type: Interventional
• Enrollment (Actual): 27
• Phase: Phase 1

Contacts and Locations

Study Locations

• Russian Federation
  • Moscow, Russian Federation, 119991
    • Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

1. Non-smoking healthy male subjects aged 18 - 45 years (inclusive);
2. Verified "healthy" status, based on standard clinical, laboratory, and instrumental examination methods;
3. Body weight ≥ 50 kg and Body Mass Index in the range from 18.5 to 30.0 kg/m2;
4. Signed the Participant Explanation Sheet and the Informed Consent Form;
5. Consent to use an adequate method of contraception throughout the study and 3 months after its completion: a condom with spermicide substance (cream, foam or suppository).

Exclusion Criteria:

1. Chronic cardiovascular, bronchopulmonary, neuroendocrine, musculoskeletal or gastrointestinal diseases, as well as immunologic, hepatic, renal, or blood diseases;
2. Laboratory abnormalities, or ECG abnormalities at Screening;
3. Systolic arterial pressure less than 90 mm Hg or above 130 mm Hg, diastolic arterial pressure less than 60 mm Hg or above 85 mm Hg, heart rate less than 60 BPM or more than 90 BPM at Screening;
4. Regular intake of drugs within 2 weeks before Screening (including herbal preparations and dietary supplements); intake of drugs that have a pronounced effect on hemodynamics, liver, kidney, or CNS function, etc. (for example, barbiturates, omeprazole, cimetidine, etc.) within 4 weeks before Screening;
5. Presence of antibodies to HIV or hepatitis C virus, presence of hepatitis В surface antigen, positive syphilis test;
6. Unstable sleeping (for example, night work, sleep disturbances, insomnia, recent return from another time zone, etc.);
7. Signs of alcohol (taking more than 10 units of alcohol per week) or drug addiction; alcohol or drugs consumption within 7 days prior to Screening; smoking within 3 months before Screening; positive drug or alcohol test at Screening;
8. Depression episodes or other mental disorders/conditions in medical history that required therapy
9. Allergy in medical history (including drug intolerance and food allergy);
10. Hypersensitivity to the active substance or to any other ingredient of the study drug. Sucrose intolerance, sucrase-isomaltase deficiency, sucrose isomaltose malabsorption, lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
11. Blood/plasma donation (450 ml or more of blood/plasma) or surgical intervention within 12 months before Screening;
12. Diseases and conditions (current or in medical history), including surgical intervention, which, according to the opinion of Investigator, may affect the absorption, distribution, metabolism, or excretion of the study drug (excluding appendectomy);
13. Participation in other clinical studies or therapy with other study drugs within 3 months before Screening;
14. Acute infectious diseases within 4 weeks before Screening;
15. Subjects unable to read or write; unwillingness to understand and follow to the procedures, defined in the Study Protocol; non-compliance with the dosing regimen or procedures, which according to the opinion of Investigator, may affect the study results or safety of study subject and prevent the subject from further participation in the study; any other associated medical or serious mental conditions making the subject not eligible to participate in the clinical study, restricting validity of obtaining the informed consent or affecting the subject's ability to participate in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: SEQUENTIAL
• Masking: NONE

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: VM-1500A-LAI 150mg; VM-1500A-LAI 150mg IM single dose	Drug: VM-1500A-LAI; VM-1500A (parent drug of elsulfavirine) IM injection dosage form; Other Names: VM-1500; VM-1500A
EXPERIMENTAL: VM-1500A-LAI 300mg; VM-1500A-LAI 300mg IM single dose	Drug: VM-1500A-LAI; VM-1500A (parent drug of elsulfavirine) IM injection dosage form; Other Names: VM-1500; VM-1500A
EXPERIMENTAL: VM-1500A-LAI 600mg; VM-1500A-LAI 600mg IM single dose	Drug: VM-1500A-LAI; VM-1500A (parent drug of elsulfavirine) IM injection dosage form; Other Names: VM-1500; VM-1500A
EXPERIMENTAL: VM-1500A-LAI 1200mg; VM-1500A-LAI 1200mg IM single dose	Drug: VM-1500A-LAI; VM-1500A (parent drug of elsulfavirine) IM injection dosage form; Other Names: VM-1500; VM-1500A
EXPERIMENTAL: VM-1500A-LAI 600 mg Multiple; VM-1500A-LAI Multiple dose (2 injections every 4 weeks)	Drug: VM-1500A-LAI; VM-1500A (parent drug of elsulfavirine) IM injection dosage form; Other Names: VM-1500; VM-1500A

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The incidence of AEs and SAEs. Concentration of VM1500A in plasma and RBCs	The incidence of adverse events (AEs) and serious adverse events (SAEs). This is an open-label study aimed to evaluate safety, tolerability, and pharmacokinetics of VM-1500A-LAI administered as single or multiple ascending doses to healthy volunteers.	4 weeks for SAD, 8 weeks for MAD

Collaborators and Investigators

• Sponsor: Viriom
• Investigators: Principal Investigator: Elena Smolyarchuk, PhD, I.M. Sechenov First Moscow State Medical University

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 21, 2019
• Primary Completion (ACTUAL): March 27, 2020
• Study Completion (ACTUAL): May 18, 2020

Study Registration Dates

• First Submitted: October 11, 2018
• First Submitted That Met QC Criteria: October 11, 2018
• First Posted (ACTUAL): October 16, 2018

Study Record Updates

• Last Update Posted (ACTUAL): December 15, 2021
• Last Update Submitted That Met QC Criteria: December 6, 2021
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Keywords: HIV-1
• Other Study ID Numbers: HIV-VM1500ALAI-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No